Tag: #NOACs

Introduction: Patients with chronic kidney disease (CKD) face an increased risk of thromboembolic complications, making anticoagulation therapy a critical part of their management. While traditional Vitamin K antagonists (VKAs) have long been used, newer Non-Vitamin K antagonist oral anticoagulants (NOACs) like rivaroxaban and apixaban are gaining traction. However, their use in renally impaired patients presents…